-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On August 9, the National Medical Insurance Administration issued a Circular on the Circumstances of 3 Companies Falsely Increasing the Prices of Raw Materials and Raising Drug Prices to Get Fund.
In accordance with the policy and supervision of “control”, it colluded with more than 50 downstream pharmaceutical agents, and adopted the method of purchasing APIs at inflated prices for 87 kinds of drugs such as cefathiamidine for injectio.
The main method of cashing out is that drug manufacturers and drug agents sign a cooperation agreement to add designated "distributors" in the procurement of APIs, and the "dealers" buy APIs at normal prices, increasing the price several times to te.
It is sold to pharmaceutical manufacturers several time.
In the name of "rising prices of raw materials and high production costs", drug manufacturers have further transmitted the falsely high prices of raw materials to factory and bidding price.
The “dealers” of APIs are actually controlled by drug agents, and they cash out the income from the price difference obtained by buying low-cost and high-selling APIs and transferring them to the drug agents for them to implement pharmaceutical commercial briber.
At present, the above-mentioned three drug manufacturers have rectified the prices of the drugs involved nationwide as required, and the procurement of some products has been stoppe.
It is reported that the above-mentioned companies are all subsidiaries of a pharmaceutical group in Guangzho.
The group recently stated in an announcement that in 2021, the above three companies will have a total gross profit of RMB 15 million for products that are withdrawn from the Internet, and a total gross profit of RMB 320 million for products with reduced prices, accounting for 320 million yua.
The audited gross profit ratio of the company in 2021 is 12% and 45% respectively; from January to March 2022, the total gross profit of the above three companies involved in withdrawing products from the Internet is RMB 12 million, and the total gross profit of products with reduced prices is RMB 102 millio.
The proportion of the company's unaudited gross profit from January to March 2022 is 25% and 13%, respectivel.
Regarding the impact of this incident that is concerned by the industry on the company, the company said, "It is expected that this incident will have a certain impact on the company's future product sales, but it will not have a significant impact on the company's operating performanc.
" At the same time, the group said , the company has taken a series of rectification measure.
Including, the three companies have been instructed to stop cooperating with relevant agents and distributors, comprehensively rectify their marketing models, reduce the price of related products or withdraw from the Internet nationwide, and remove and suspend the responsible persons of the three companie.
The inflated pricing of drugs was withdrawn from the Internet, procurement was stopped, and prices were rectifie.
The relevant responsible persons were dismissed and suspende.
This series of violation costs is believed to be enough to wake up the industr.
However, behind the above-mentioned pharmaceutical companies inflating the price of raw materials and raising the price of drugs, the analysis believes that it may be related to the exclusive varieties of related product.
Since the cost of raw materials accounts for more than half of the total cost of drugs, the rest is basically sales expense.
, the exclusive variety has a certain operating space to inflate the price of raw material.
What needs to be seen is that in recent years, in order to reduce the burden of patients' drug costs, the national level has cracked down on inflated drug prices and cheating behaviors, and local governments have also successively issued notices on the withdrawal of related drugs from the Internet and price rectificatio.
For pharmaceutical companies, withdrawing from the network means losing the qualification to win the bid, and it is difficult to enter the hospital for sales, which is not conducive to the long-term steady growth of corporate performanc.
The National Medical Insurance Bureau stated that it will continue to guide the provinces with relevant departments, according to the implementation of corporate rectification and the facts of violations of laws and regulations identified by relevant departments, to do a good job in the evaluation of pharmaceutical prices and recruitment credit, and to cooperate with relevant departments to continue to correct the field of pharmaceutical purchase and sale.
win.
At the same time, it requires the majority of pharmaceutical production and operation enterprises to take a warning, actively regulate their own business behavior, abide by the statutory pricing principles of fairness and reasonableness, honesty and credit, and consistent quality and price, and work together to create a clean market environment and industry ecolog.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
In accordance with the policy and supervision of “control”, it colluded with more than 50 downstream pharmaceutical agents, and adopted the method of purchasing APIs at inflated prices for 87 kinds of drugs such as cefathiamidine for injectio.
The main method of cashing out is that drug manufacturers and drug agents sign a cooperation agreement to add designated "distributors" in the procurement of APIs, and the "dealers" buy APIs at normal prices, increasing the price several times to te.
It is sold to pharmaceutical manufacturers several time.
In the name of "rising prices of raw materials and high production costs", drug manufacturers have further transmitted the falsely high prices of raw materials to factory and bidding price.
The “dealers” of APIs are actually controlled by drug agents, and they cash out the income from the price difference obtained by buying low-cost and high-selling APIs and transferring them to the drug agents for them to implement pharmaceutical commercial briber.
At present, the above-mentioned three drug manufacturers have rectified the prices of the drugs involved nationwide as required, and the procurement of some products has been stoppe.
It is reported that the above-mentioned companies are all subsidiaries of a pharmaceutical group in Guangzho.
The group recently stated in an announcement that in 2021, the above three companies will have a total gross profit of RMB 15 million for products that are withdrawn from the Internet, and a total gross profit of RMB 320 million for products with reduced prices, accounting for 320 million yua.
The audited gross profit ratio of the company in 2021 is 12% and 45% respectively; from January to March 2022, the total gross profit of the above three companies involved in withdrawing products from the Internet is RMB 12 million, and the total gross profit of products with reduced prices is RMB 102 millio.
The proportion of the company's unaudited gross profit from January to March 2022 is 25% and 13%, respectivel.
Regarding the impact of this incident that is concerned by the industry on the company, the company said, "It is expected that this incident will have a certain impact on the company's future product sales, but it will not have a significant impact on the company's operating performanc.
" At the same time, the group said , the company has taken a series of rectification measure.
Including, the three companies have been instructed to stop cooperating with relevant agents and distributors, comprehensively rectify their marketing models, reduce the price of related products or withdraw from the Internet nationwide, and remove and suspend the responsible persons of the three companie.
The inflated pricing of drugs was withdrawn from the Internet, procurement was stopped, and prices were rectifie.
The relevant responsible persons were dismissed and suspende.
This series of violation costs is believed to be enough to wake up the industr.
However, behind the above-mentioned pharmaceutical companies inflating the price of raw materials and raising the price of drugs, the analysis believes that it may be related to the exclusive varieties of related product.
Since the cost of raw materials accounts for more than half of the total cost of drugs, the rest is basically sales expense.
, the exclusive variety has a certain operating space to inflate the price of raw material.
What needs to be seen is that in recent years, in order to reduce the burden of patients' drug costs, the national level has cracked down on inflated drug prices and cheating behaviors, and local governments have also successively issued notices on the withdrawal of related drugs from the Internet and price rectificatio.
For pharmaceutical companies, withdrawing from the network means losing the qualification to win the bid, and it is difficult to enter the hospital for sales, which is not conducive to the long-term steady growth of corporate performanc.
The National Medical Insurance Bureau stated that it will continue to guide the provinces with relevant departments, according to the implementation of corporate rectification and the facts of violations of laws and regulations identified by relevant departments, to do a good job in the evaluation of pharmaceutical prices and recruitment credit, and to cooperate with relevant departments to continue to correct the field of pharmaceutical purchase and sale.
win.
At the same time, it requires the majority of pharmaceutical production and operation enterprises to take a warning, actively regulate their own business behavior, abide by the statutory pricing principles of fairness and reasonableness, honesty and credit, and consistent quality and price, and work together to create a clean market environment and industry ecolog.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.